A legitimate online GLP-1 path has five parts: an evaluation by a licensed clinician you can name and contact, a US-licensed pharmacy you can verify with NABP or your state board of pharmacy, an FDA-approved product shipped in the manufacturer's sealed packaging, a price you can see before you enter a card, and no pressure to buy a bundle. If a site skips the clinician, ships a powder you mix yourself, or labels the vial "research use only," you are not buying medicine — you are buying an unregulated chemical.
Most women reading this did not arrive here curious. You arrived because a plan said no, or a pharmacy quoted four figures, or a friend mentioned a site charging $129 a month and you want to know what the catch is. This page will not tell you to start or stop anything, and it does not recommend a provider. It gives you the checks a pharmacist would run.
What "legitimate" actually means online
Telehealth for GLP-1s is legal and normal. The line is not "online versus in person" — it is whether real clinical and pharmacy licensing sits behind the transaction. The scale of the problem is not small: the FDA, citing the National Association of Boards of Pharmacy, says only about 5% of roughly 35,000 active online pharmacy websites comply with US pharmacy laws and practice standards.
A real evaluation asks about your weight history, your other conditions and medications, personal or family history of medullary thyroid carcinoma or MEN 2, pancreatitis, gallbladder disease, pregnancy or plans to become pregnant, and whether you have diabetic retinopathy. It usually asks for recent labs or vitals. It takes more than ninety seconds. If a form ends with instant approval and a checkout page, no one evaluated you; a script was generated to complete a sale.
A real pharmacy is licensed in the state where you live, dispenses a drug the FDA has approved, and ships it in the manufacturer's carton with the patient leaflet, an NDC number and a lot number you could look up. A real prescriber has a name, a licence number and a state — and can be reached again when something goes wrong at 9pm on a Sunday, which is the moment that separates a clinical service from a storefront.
The red-flag table
| Red flag | What it actually tells you |
|---|---|
| "Research peptide," "research use only," "not for human consumption" | The single biggest tell of an illegal source. The FDA has issued warning letters to companies selling semaglutide, tirzepatide and other GLP-1 compounds under this label while marketing them to consumers. The wording is a legal dodge, not a product category. These are unapproved drugs of unknown identity, purity, potency and sterility. |
| No clinician contact — a form, then instant approval | No one assessed your contraindications. There is also nobody to call if you develop severe abdominal pain or persistent vomiting. |
| Arrives as a powder or a multi-dose vial you draw up yourself | FDA-approved GLP-1s are dispensed ready to use in pens or single-dose vials. A vial plus a syringe means you are calculating your own dose. The FDA has documented adverse events, some requiring hospitalisation, in which patients drew up 5 to 20 times the intended dose from a multi-dose vial — for example, giving 50 insulin units instead of the intended 5. |
| Price far below the manufacturer's own cash price | Novo Nordisk and Eli Lilly sell direct for a few hundred dollars a month (see the table below). Nobody legitimately undercuts the manufacturer by 80%. A "$99 semaglutide" is not the same molecule in the same supply chain. |
| Payment by crypto, Zelle, Venmo, wire or "friends and family" | Payment rails that cannot be reversed and cannot be traced. Licensed pharmacies take ordinary card payments. |
| No verifiable US pharmacy licence | If you cannot find the dispensing pharmacy's name, state and licence number, there is no accountable dispenser. See the verification steps below. |
| Sold through Instagram, TikTok, Telegram, Reddit DMs or a marketplace listing | Prescription drugs are not sold this way in the US. Ever. |
| Unbranded vial, handwritten or peel-off label, no NDC or lot number | Counterfeits are real. The FDA has warned about counterfeit Ozempic that reached the US supply chain, including counterfeit needles whose sterility could not be confirmed. |
| "Subscribe to a 6-month bundle to lock this price" with a countdown timer | Prepaid, non-refundable bundles transfer the risk to you. If you cannot tolerate the drug in week three, you have paid for month six. |
How to verify a pharmacy in ten minutes
- Find the dispensing pharmacy's name. It is often not the telehealth brand. Look in the FAQ, the terms, or ask support directly: "Which pharmacy dispenses my prescription, and in which state is it licensed?" A refusal to answer is an answer.
- Check NABP. The National Association of Boards of Pharmacy runs the .pharmacy Verified Websites Program and a Buy Safely lookup that flags sites as verified or not recommended. A web address ending in .pharmacy is accredited — and unlike a trust-badge graphic, the domain cannot be faked.
- Check your state board. The FDA's BeSafeRx pages link to every state board of pharmacy licence database. The FDA's own guidance is blunt: if your online pharmacy is not listed there, do not use it. A pharmacy that is not licensed in your state cannot legally mail to you.
- Ask what product will be dispensed. The honest answer names a drug and a manufacturer — Wegovy or Ozempic (semaglutide, Novo Nordisk), Zepbound or Mounjaro (tirzepatide, Eli Lilly). "Compounded semaglutide" is a different answer and belongs to a different regulatory category.
- Get the prescriber's full name and licence state before you pay, and confirm how you reach them for a side-effect question. Also confirm there is a US phone number and a US physical address.
Where compounded GLP-1s stand now
Compounded semaglutide and tirzepatide are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or manufacturing quality, so no regulator has confirmed what is in the vial, how much of it, or whether it is sterile. That is the single most important sentence on this page, and it is true no matter how professional the website looks.
This is also where most 2024-era articles are stale. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025 — and the legal basis for compounding copies of a commercially available drug largely depends on that drug being in shortage. In spring 2026 the agency went further: in a Federal Register notice published on 1 May 2026 (comments closed 29 June 2026) it proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, on a finding of no clinical need. If finalised, that would stop outsourcing facilities compounding these drugs from bulk ingredient. As of 12 July 2026 it is a proposal, not a final rule — check its status before relying on it.
We are not going to tell you to use or avoid compounded product; that is a decision for you and a clinician, and narrow personalised needs do exist. What you are entitled to know is the documented harm. The FDA has warned specifically about dosing errors with compounded injectable semaglutide supplied as a multi-dose vial and syringe: patients unfamiliar with drawing up small volumes gave themselves 5 to 20 times the intended dose — 50 units instead of 5 on a U-100 insulin syringe — and some were hospitalised. By early 2025 the agency had received hundreds of adverse-event reports involving compounded semaglutide and compounded tirzepatide. It has also documented unapproved salt forms (semaglutide sodium, semaglutide acetate — not the approved active ingredient), products shipped warm without adequate ice, and cases where the compounding pharmacy printed on the label did not exist.
So if a site is still mass-marketing compounded GLP-1s in 2026, ask which pharmacy, under which licence, in what form (pen, single-dose vial, or vial-and-syringe), and on what clinical basis. Then decide with your prescriber.
The manufacturers' own direct channels
Many people do not realise the drug companies sell direct to cash-paying patients, which removes an entire layer of middlemen. These channels matter here for one reason: they set the price floor that every other offer should be judged against. The prices below were checked on 12 July 2026 on the manufacturers' own pages. They are promotional, they carry conditions, and they change — verify on the day you buy.
| Channel | Product | Self-pay price listed |
|---|---|---|
| NovoCare Pharmacy (Novo Nordisk) | Wegovy and Ozempic pens | $199/month as an introductory offer covering the first two monthly fills of the starting doses (0.25 mg and 0.5 mg), listed through 31 December 2026; then $349/month for Wegovy 0.25–2.4 mg and Ozempic 0.25–1 mg. Higher strengths cost more — Wegovy HD 7.2 mg was listed at $399/month and Ozempic 2 mg at $499/month. |
| NovoCare Pharmacy | Wegovy in pill form (oral semaglutide) | $149/month for the listed doses on a limited-time offer; the 4 mg offer was listed through 31 August 2026, after which it rises to $199/month. |
| LillyDirect (Eli Lilly) | Zepbound single-dose vials | $299/month (2.5 mg), $399/month (5 mg), $449/month (7.5–15 mg) under Lilly's self-pay programme, which requires refilling within 45 days of your previous delivery. Outside that window the higher strengths revert to list — 12.5 mg and 15 mg were $849 and $1,049. |
Both channels still require a prescription. Both will connect you to telehealth if you do not have a prescriber, and both let your own doctor send the script to their pharmacy — usually the better route, because your own doctor knows the rest of your chart. Neither is a shortcut past clinical evaluation, and neither is a reason to start a drug you would not otherwise take. Naming them is not a recommendation: it is a benchmark, so that when a site quotes you $99 you know exactly what that number is telling you.
Disclosure: VidaBeacon may earn a commission from some telehealth and pharmacy links elsewhere on this site, including on our GLP-1 online care comparison. We have no financial relationship with Novo Nordisk or Eli Lilly. Commissions never buy a recommendation, we do not accept payment to omit a red flag, and no provider is recommended on this page.
If you have insurance: the questions that actually work
We cannot tell you what your plan covers — plans differ by employer, by state and by year, and anyone online who claims to know yours is guessing. What we can do is give you the wording that gets a real answer. Call the member number on your card and ask:
- "Is [drug name] on my formulary, at which tier, and for which indication — diabetes, weight, or cardiovascular risk reduction?"
- "Does my employer's plan carry the anti-obesity medication rider, or is that excluded?"
- "What are the prior-authorisation criteria in writing, and what documentation does my prescriber need to send?"
- "If it is denied, what is the appeal deadline, and is there a formulary exception process?"
Get a reference number for the call, and the name of the person you spoke to.
If you are on Medicare: a CMS pilot called the Medicare GLP-1 Bridge began on 1 July 2026 and is scheduled to run to 31 December 2027. Eligible Part D members pay a flat $50 monthly copay for covered weight-management GLP-1s, and the copay does not rise as your dose rises. Two details people miss: eligibility is BMI-based with clinical criteria (broadly, a BMI of 35 or more, or a lower BMI with qualifying conditions), and the $50 does not count toward your Part D deductible or toward the annual out-of-pocket cap. Which products are covered is set by the programme and by your plan. The rules are new and still moving, so confirm with your own Part D plan and with Medicare directly, not with a marketing page. (Checked 12 July 2026.)
One thing we will never help with: misstating a diagnosis, a weight, a symptom or a history to obtain coverage. It is insurance fraud, it can void your policy, and it puts a false condition in your medical record that follows you for years. If you are denied, appeal on the truth — denials are overturned more often than people expect, and a prescriber's letter documenting what you have actually tried is the thing that moves them.
Our cost and coverage estimator can help you frame the numbers before that call.
About dosing, briefly and carefully
The FDA labels for these drugs publish a fixed escalation schedule — a low starting dose held for several weeks, then stepwise increases at defined intervals, up to a maximum. That is public reference information, and you can read it on the label at DailyMed. It is not an instruction, and it is not a plan for you. Your prescriber sets your dose and decides whether and when to change it, based on your tolerance, your other conditions and your other medications.
Do not adjust, split, stretch or skip doses on your own to save money, and do not double up after a missed dose to "catch up." Ask your prescriber what to do about a missed dose before you ever miss one — the right answer depends on how much time has passed, and it is their call, not a rule you should improvise. If cost is what is driving the impulse to stretch a pen — and for a lot of women it is — say so out loud to your prescriber. That is a clinical conversation with legitimate options, not a personal failure. For the reference detail, see what the GLP-1 labels publish about dosing.
When to talk to a doctor — and when to stop and get help now
Seek urgent medical care for severe, persistent abdominal pain, especially pain radiating to your back with vomiting (possible pancreatitis); signs of a serious allergic reaction such as swelling of the face, lips or throat, or difficulty breathing; persistent vomiting with signs of dehydration; sudden vision changes; or severe right-upper-abdominal pain with fever or yellowing of the skin or eyes (possible gallbladder problem).
Talk to your prescriber before starting or continuing if you have a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, diabetic retinopathy, or if you are pregnant, breastfeeding, or could become pregnant. Tell them about every other medication and supplement — GLP-1s slow stomach emptying, which can change how other drugs are absorbed, and they interact with insulin and sulfonylureas. Flag any upcoming surgery or procedure with anaesthesia.
Bring it to a clinician, not a chat widget, if you bought from a source you now suspect was illegitimate. Take the vial, the packaging and the seller's website name with you. You will not be judged, and knowing exactly what you took — or knowing that nobody can know what you took — changes what a clinician looks for.
If you want the clinical background before you spend anything, start with how GLP-1 drugs actually work, Wegovy vs Ozempic and the side effects worth planning for. For the molecule itself, see semaglutide. And if you want a structured way to compare online options rather than a recommendation, use our GLP-1 online care comparison and score every provider against the red-flag table above.
